EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy

Fabiana Letizia Cecere, Ettore D'Argento, Francesco Gelsomino, Francesco Pesola, Paolo Bironzo, Salvatore Grisanti, Laura Bonanno, Gianluca Spitaleri, Diletta Valsecchi, Ilaria Marcon, Diego Cortinovis

Clinical and Experimental Medicine · 2025

DOI: 10.1007/s10238-025-01934-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2025. Verfasst von Fabiana Letizia Cecere und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 2, IRCCS Regina Elena National Cancer Institute Rome, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins c-met, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with advanced non-small cell lung cancer (NSCLC), MET exon 14 ( MET ex14) skipping mutations are rare and are associated with a poor prognosis. Capmatinib, a selective oral MET inhibitor, was recently approved for the treatment of advanced MET ex14 skipping NSCLC. However, data from real-world experiences are limited. This was a retrospective analysis using real-world data from Italian patients with advanced MET ex14 skipping NSCLC who had received at least one treatment with immunotherapy and/or platinum-based chemotherapy and received compassionate use treatment with capmatinib. Patient characteristics, treatment details, discontinuations, and adverse events are reported. Overall, 53 patients received capmatinib after receiving treatment with immunotherapy and/or platinum-based chemotherapy in Italy. Patients had a median age of 74 years, mostly metastatic disease (92.5% of patients), and previously received one (66.0%) or more (2: 28.3%; 3: 5.7%) lines of standard treatment (immunotherapy and/or platinum-based chemotherapy). Most patients (98.1%) started treatment with capmatinib at the full recommended dose of 400 mg twice daily and 77.4% did not require a dose reduction. Twenty-four patients (45.3%) discontinued treatment; the most frequent reason for discontinuing treatment was disease progression, with a median estimated time to treatment discontinuation of 15.2 months. This real-world retrospective analysis confirms that capmatinib is a valuable treatment option for difficult-to-treat MET ex14 skipping NSCLC, in agreement with the data from the registration trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins c-metLung NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsExonsMutationRetrospective StudiesCompassionate Use TrialsItalyDisease ProgressionHumansMaleFemaleMiddle AgedAgedAged, 80 and overBenzamidesImidazolesTriazinesTreatment OutcomeNeoplasm Staging

Stichwörter der Autor:innen

METex14 skippingCapmatinibMETNon-small cell lung cancerOncogenic driverTargeted therapy

Substanzen

capmatinibMET protein, humanProto-Oncogene Proteins c-metBenzamidesImidazolesTriazinesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Medical Oncology 2, IRCCS Regina Elena National Cancer Institute Rome, Rome, Italy.
  • Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Department of Oncology, University of Torino, AOU S. Luigi Gonzaga, Orbassano, Italy.
  • Medical Oncology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.

Zitieren

APA

Cecere, F. L., D'Argento, E., Gelsomino, F., Pesola, F., Bironzo, P., Grisanti, S., Bonanno, L., Spitaleri, G., Valsecchi, D., Marcon, I., & Cortinovis, D. (2025). Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-025-01934-2

Vancouver

Cecere FL, D'Argento E, Gelsomino F, Pesola F, Bironzo P, Grisanti S, et al. Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy. Clinical and Experimental Medicine. 2025. doi:10.1007/s10238-025-01934-2

BibTeX
@article{Cecere2025,
  author = {Cecere, Fabiana Letizia and D'Argento, Ettore and Gelsomino, Francesco and Pesola, Francesco and Bironzo, Paolo and Grisanti, Salvatore and Bonanno, Laura and Spitaleri, Gianluca and Valsecchi, Diletta and Marcon, Ilaria and Cortinovis, Diego},
  title = {Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy},
  journal = {Clinical and Experimental Medicine},
  year = {2025},
  doi = {10.1007/s10238-025-01934-2}
}
Kostenlos starten →